RESUMEN
Switch/sucrose nonfermenting complex subunits, such as BRG1, INI1, and ARID1B, are inactivated in a subset of endometrial undifferentiated carcinoma and dedifferentiated carcinoma (DC). Limited information is currently available on their prevalence in other subtypes or the nosological status of endometrial carcinoma with their deficiencies. This study immunohistochemically examined the expression status of BRG1, INI1, and ARID1B using 570 archived cases of endometrial carcinoma and carcinosarcoma resected at a single institution. We identified 1 BRG1-deficient undifferentiated carcinoma, 8 BRG1/INI1/ARID1B-deficient DC, and 3 BRG1-deficient clear-cell carcinomas. None of the cases of endometrioid and serous carcinomas or carcinosarcoma showed deficiencies of these subunits. We then compared 8 BRG1/INI1/ARID1B-deficient DC with 6 BRG1/INI1/ARID1B-intact DC and 28 carcinosarcomas, the latter of which was often confused with DC. Histologically, BRG1/INI1/ARID1B-intact and BRG1/INI1/ARID1B-deficient DC shared a monotonous solid appearance with rhabdoid and epithelioid cells and a myxoid stroma; however, abrupt keratinization and cell spindling was absent in BRG1/INI1/ARID1B-deficient tumors. The median overall survival of patients with BRG1/INI1/ARID1B-deficient DC was 3.8 months, which was worse than those with BRG1/INI1/ARID1B-intact DC (P=0.008) and with carcinosarcoma (P=0.004). BRG1/INI1/ARID1B-deficient DC may be a separate entity with an aggressive behavior to be distinguished from BRG1/INI1/ARID1B-intact DC and carcinosarcoma. Regarding clear-cell carcinoma (n=12), BRG1 deficiency appeared to be mutually exclusive with abnormal ARID1A, BRM, and p53 expression. Further studies are needed to clarify whether BRG1 deficiency plays a role in the pathogenesis of clear-cell carcinoma.
Asunto(s)
Biomarcadores de Tumor/deficiencia , Carcinoma/química , Carcinosarcoma/química , ADN Helicasas/deficiencia , Proteínas de Unión al ADN/deficiencia , Neoplasias Endometriales/química , Inmunohistoquímica , Proteínas Nucleares/deficiencia , Proteína SMARCB1/deficiencia , Factores de Transcripción/deficiencia , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/patología , Carcinoma/cirugía , Carcinoma Endometrioide/química , Carcinoma Endometrioide/patología , Carcinoma Endometrioide/cirugía , Carcinosarcoma/patología , Carcinosarcoma/cirugía , Desdiferenciación Celular , Neoplasias Endometriales/patología , Neoplasias Endometriales/cirugía , Femenino , Humanos , Persona de Mediana EdadRESUMEN
Uterine carcinosarcoma (UCS) represents a true example of cancer associated with epithelial-mesenchymal transition (EMT), which exhibits cancer stem cell (CSC)-like traits. Although S100A4 is an inducer of EMT, little is known about its involvement in UCS tumorigenesis. Herein, we focused on the functional role of S100A4 during development of UCS. Expression of S100A4 and molecules associated with its function were also examined in 35 UCS cases. In endometrial carcinoma cell lines, S100A4 promoter activity and mRNA levels were significantly increased by the transfection of NF-κB/p65, independent of a putative κB-binding site in the promoter. Cells stably overexpressing S100A4 showed enhancement of CSC properties, along with decreased cell proliferation and acceleration of cell migration. These phenotypes were abrogated in S100A4-knockdown cells. A combination of S100A4 antibody-mediated co-immunoprecipitation and shotgun proteomics analysis revealed that S100A4 strongly interacted with non-muscle myosin II (NMII) heavy chains, including myosin 9 and myosin 14. Specific inhibition of NMII by blebbistatin phenocopied S100A4 overexpression and induced a fibroblast-like morphology. In clinical samples, S100A4 score was significantly higher in sarcomatous as compared with carcinomatous components of UCS, and was positively correlated with ALDH1, Slug, and vimentin scores, and inversely with Ki-67 labeling indices. These findings suggest that an S100A4/NMII-related signaling cascade may contribute to the establishment and maintenance of EMT/CSC properties, along with changes in cell proliferation and migration capability. These events may be initiated in carcinomatous components in UCS and lead to divergent sarcomatous differentiation.
Asunto(s)
Carcinosarcoma/patología , Transición Epitelial-Mesenquimal/fisiología , Proteína de Unión al Calcio S100A4 , Transducción de Señal/fisiología , Neoplasias Uterinas/patología , Carcinosarcoma/química , Línea Celular Tumoral , Femenino , Técnicas de Silenciamiento del Gen , Humanos , Proteína de Unión al Calcio S100A4/genética , Proteína de Unión al Calcio S100A4/metabolismo , Neoplasias Uterinas/química , Útero/química , Útero/patologíaAsunto(s)
Carcinoma Basocelular/patología , Carcinosarcoma/patología , Neoplasias Cutáneas/patología , Anciano de 80 o más Años , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Carcinoma Basocelular/química , Carcinoma Basocelular/genética , Carcinosarcoma/química , Carcinosarcoma/genética , Oído , Humanos , Masculino , Neoplasias Cutáneas/química , Neoplasias Cutáneas/genéticaRESUMEN
Several subtypes of high-grade endometrial carcinomas (ECs) contain an undifferentiated component of non-epithelial morphology, including undifferentiated and dedifferentiated carcinomas and carcinosarcomas (CSs). The mechanism by which an EC undergoes dedifferentiation has been the subject of much debate. The epithelial-mesenchymal transition (EMT) is one of the mechanisms implicated in the transdifferentiation of high-grade carcinomas. To improve our understanding of the role of EMT in these tumors, we studied a series of 89 carcinomas including 14 undifferentiated/dedifferentiated endometrial carcinomas (UECs/DECs), 49 CSs (21 endometrial, 29 tubo-ovarian and peritoneal), 17 endometrioid carcinomas (grade 1-3), and 9 high-grade serous carcinomas of the uterus, using a panel of antibodies targeting known epithelial markers (Pan-Keratin AE1/AE3 and E-cadherin), mesenchymal markers (N-cadherin), EMT transcription factors (TFs) (ZEB1, ZEB2, TWIST1), PAX8, estrogen receptors (ER), progesterone receptors (PR), and the p53 protein. At least one of the three EMT markers (more frequently ZEB1) was positive in the sarcomatous component of 98% (n = 48/49) of CSs and 98% (n = 13/14) of the undifferentiated component of UEC/DEC. In addition, 86% of sarcomatous areas of CSs and 79% of the undifferentiated component of UEC/DEC expressed all three EMT-TFs. The expression of these markers was associated with the loss of or reduction in epithelial markers (Pan-keratin, E-cadherin), PAX8, and hormone receptors. In contrast, none of the endometrioid and serous endometrial carcinomas expressed ZEB1, while 6% and 36% of endometrioid and 11% and 25% of serous carcinomas focally expressed ZEB2 and TWIST1, respectively. Although morphologically different, EMT appears to be implicated in the dedifferentiation in both CSs and UEC/DEC. Indeed, we speculate that the occurrence of EMT in a well differentiated endometrioid carcinoma may consecutively lead to a dedifferentiated and undifferentiated carcinoma, while in a type II carcinoma, it may result in a CS.
Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma/química , Transición Epitelial-Mesenquimal , Neoplasias Uterinas/química , Carcinoma/clasificación , Carcinoma/patología , Carcinoma Endometrioide/química , Carcinoma Endometrioide/patología , Carcinosarcoma/química , Carcinosarcoma/patología , Desdiferenciación Celular , Neoplasias Endometriales/química , Neoplasias Endometriales/patología , Femenino , Humanos , Inmunohistoquímica , Clasificación del Tumor , Proteínas Nucleares/análisis , Estudios Retrospectivos , Proteína 1 Relacionada con Twist/análisis , Neoplasias Uterinas/clasificación , Neoplasias Uterinas/patología , Caja Homeótica 2 de Unión a E-Box con Dedos de Zinc/análisis , Homeobox 1 de Unión a la E-Box con Dedos de Zinc/análisisRESUMEN
Mesonephric carcinomas of the gynecologic tract are neoplasms that are often under-recognized due to their varied morphologic appearances. Recently, GATA3 and TTF1 have been reported to be useful immunohistochemical markers for distinguishing mesonephric carcinomas from its morphologic mimics. Herein, we compared the performance of GATA3 and TTF1 to the traditional markers used for mesonephric carcinomas, CD10 and calretinin. We studied 694 cases: 8 mesonephric carcinomas (7 cervical [includes 3 mesonephric carcinosarcomas], 1 vaginal), 5 mesonephric-like carcinomas (4 uterine corpus, 1 ovarian), 585 endometrial adenocarcinomas, and 96 cervical adenocarcinomas. Mesonephric-like carcinomas were defined as tumors exhibiting the classic morphologic features of mesonephric carcinoma, but occurring outside of the cervix and without convincing mesonephric remnants. GATA3 had the highest sensitivity and specificity (91% and 94%) compared with TTF1 (45% and 99%), CD10 (73% and 83%), and calretinin (36% and 89%). GATA3, however, also stained a substantial number of uterine carcinosarcomas (23/113, 20%). TTF1 was positive in 5/5 (100%) mesonephric-like carcinomas and only 1/8 (13%) mesonephric carcinomas. In 4/6 (67%) TTF1 positive cases, GATA3 exhibited an inverse staining pattern with TTF1. In summary, GATA3 was the best overall marker for mesonephric and mesonephric-like carcinomas, but cannot be used to distinguish mesonephric carcinosarcomas from Müllerian carcinosarcomas. The inverse staining pattern between GATA3 and TTF1, suggests that TTF1 may be useful when GATA3 is negative in small biopsies where mesonephric or mesonephric-like carcinoma is suspected. The greater TTF1 positivity in mesonephric-like carcinomas suggests they may be biologically different from prototypical mesonephric carcinomas.
Asunto(s)
Adenocarcinoma/química , Biomarcadores de Tumor/análisis , Calbindina 2/análisis , Carcinosarcoma/química , Neoplasias Endometriales/química , Factor de Transcripción GATA3/análisis , Conductos Paramesonéfricos/química , Neprilisina/análisis , Factor Nuclear Tiroideo 1/análisis , Neoplasias del Cuello Uterino/química , Neoplasias Vaginales/química , Conductos Mesonéfricos/química , Adenocarcinoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Carcinosarcoma/patología , Diagnóstico Diferencial , Neoplasias Endometriales/patología , Femenino , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Conductos Paramesonéfricos/metabolismo , Valor Predictivo de las Pruebas , Análisis de Matrices Tisulares , Neoplasias del Cuello Uterino/patología , Neoplasias Vaginales/patología , Conductos Mesonéfricos/patologíaAsunto(s)
Carcinosarcoma/patología , Fallo Renal Crónico/terapia , Diálisis Peritoneal , Neoplasias Peritoneales/patología , Diálisis Renal , Anciano , Biomarcadores de Tumor/análisis , Biopsia , Carcinosarcoma/química , Carcinosarcoma/diagnóstico por imagen , Resultado Fatal , Humanos , Inmunohistoquímica , Queratinas/análisis , Fallo Renal Crónico/diagnóstico , Masculino , Neoplasias Peritoneales/química , Neoplasias Peritoneales/diagnóstico por imagenRESUMEN
The association of sarcomatoid carcinoma (SC) with small cell carcinoma (SCC) has not been systematically studied. We identified 39 consult cases between 2001 and 2016 with available slides for review in 28 cases. There were 19 men and 9 women (mean age: 78 years [51-89]). In 26 (92.8%) cases, the sarcomatoid component had nonspecific malignant spindle cells, 4 (14%) chondrosarcoma, 2 (7%) myxoid sarcomatous, 1 (3.5%) osteosarcoma, and 1 (3.5%) rhabdomyosarcoma. The predominant component was SCC in 11 (39%) cases, urothelial carcinoma in 6 (21%), sarcomatoid in 3 (10%), and equal sarcomatoid and SCC in 8 (29%). There were 3 morphological groups: group 1 (18/28 [64%]) showed a gradual transition from SCC to other components; group 2 (5/28 [18%]) had an abrupt transition from SCC to other components; and in group 3 (5/28 [18%]), the SCC was separate from other components. In group 1, 12 (66%) cases of SCC showed a gradual transition to sarcomatoid areas; 3 (17%) to urothelial carcinoma; and 3 (17%) to multiple components including squamous cell carcinoma, urothelial carcinoma, and sarcomatoid. Mortality did not differ based on pathological groups. The 36-month actuarial risk of death was 64.3%. The multitude of different components in these tumors is further evidence of the remarkable ability of carcinoma of the bladder to show divergent differentiation with, in some cases, gradual transition between SCC and other elements including sarcomatoid. Greater recognition of this entity with chemotherapy targeted to the various histological elements may have important therapeutic implications.
Asunto(s)
Carcinoma de Células Pequeñas/patología , Carcinosarcoma/patología , Neoplasias de la Vejiga Urinaria/patología , Urotelio/patología , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/análisis , Biopsia , Carcinoma de Células Pequeñas/química , Carcinoma de Células Pequeñas/tratamiento farmacológico , Carcinoma de Células Pequeñas/mortalidad , Carcinosarcoma/química , Carcinosarcoma/tratamiento farmacológico , Carcinosarcoma/mortalidad , Bases de Datos Factuales , Diagnóstico Diferencial , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/química , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/mortalidad , Urotelio/químicaRESUMEN
OBJECTIVE: Uterine sarcomas (US) and carcinosarcomas (CS) are rare, aggressive cancers. The lack of reliable preclinical models hampers the search for new treatment strategies and predictive biomarkers. To this end, we established and characterized US and CS patient-derived xenograft (PDX) models. METHODS: Tumor fragments of US and CS were subcutaneously implanted into immunocompromised mice. Engrafted xenograft and original tumors were compared by means of histology, immunohistochemistry, whole-genome low-coverage sequencing for copy number variations, and RNA sequencing. RESULTS: Of 13 implanted leiomyosarcomas (LMS), 10 engrafted (engraftment rate of 77%). Also 2 out of 7 CS (29%) and one high-grade US (not otherwise specified) models were successfully established. LMS xenografts showed high histological similarity to their corresponding human tumors. Expression of desmin and/or H-caldesmon was detected in 8/10 LMS PDX models. We noticed that in CS models, characterized by the concomitant presence of a mesenchymal and an epithelial component, the relative distribution of the components is varying over the generations, as confirmed by changes in vimentin and cytokeratin expression. The similarity in copy number profiles between original and xenograft tumors ranged from 57.7% to 98.2% for LMS models and from 47.4 to 65.8% for CS models. Expression pattern stability was assessed by clustering RNA expression levels of original and xenograft tumors. Six xenografts clustered together with their original tumor, while 3 (all LMS) clustered apart. CONCLUSIONS: We present here a panel of clinically annotated uterine sarcoma and carcinosarcoma PDX models, which will be a useful tool for preclinical testing of new therapies.
Asunto(s)
Carcinosarcoma/patología , ADN de Neoplasias/análisis , Modelos Animales de Enfermedad , Xenoinjertos/patología , Leiomiosarcoma/patología , ARN Neoplásico/análisis , Neoplasias Uterinas/patología , Adulto , Anciano , Animales , Proteínas de Unión a Calmodulina/análisis , Carcinosarcoma/química , Carcinosarcoma/genética , Variaciones en el Número de Copia de ADN , Desmina/análisis , Femenino , Expresión Génica , Supervivencia de Injerto , Xenoinjertos/química , Humanos , Leiomiosarcoma/química , Leiomiosarcoma/genética , Ratones , Persona de Mediana Edad , Trasplante de Neoplasias , Análisis de Secuencia de ARN , Trasplante Heterólogo , Neoplasias Uterinas/química , Neoplasias Uterinas/genéticaRESUMEN
Objective: To investigate the clinic feature, pathology, therapy and prognosis of the sarcomatoid caricinoma or carcinosarcoma of the larynx. Methods: We reviewed the clinical records of 7 patients with laryngeal carcinosarcoma /sarcomatoid caricinoma who were treated at our hospital between June 1996 and August 2016. All patients were men (mean age, 65.9 years; range, 52 to 94 years). Among 7 patients, 6 had a history of smoking; 2 underwent radiotherapy; and 5 patients who didn't undergo radiotherapy complained of hoarseness. The glottis was the most frequent site of involvement. Most tumors exhibited a polypold or pedunculated gross morphology. Among the 5 patients who didn't undergo a radiotherapy, 2 were in stage â , 2 in stageâ ¡, and 1 in stage â ¢. The other 2 cases underwent surgeries and radiotherapy were staged. Results: All 7 patients received surgeries, without lymph node metastasis. All the tumors were pathologically carcinosarcoma/sarcomatoid carcinoma. With immunohistochemistry examination, Vimetin was positive in all tumors, SMA positive in 3 tumors, S-100 positive in 1 tumors, but CD-68, HMB-45 or Myglobin was negative in all tumors. With follows-up from 3 months to 20 years, of 7 patients, 4 survived without recurrent, 1 dead, and 2 lost connection. Conclusions: Both of the carcinosarcoma and the sarcomatoid carcinoma of larynx contain pathologically carcinoma and sarcoma. Surgery is the best choice for laryngeal sarcomatoid carcinoma, and these patients without a undergoing radiotherapy before surgery or these with little sarcoma in tumors show better prognosis.
Asunto(s)
Carcinosarcoma/patología , Carcinosarcoma/terapia , Neoplasias Laríngeas/patología , Neoplasias Laríngeas/terapia , Anciano , Anciano de 80 o más Años , Carcinosarcoma/química , Carcinosarcoma/mortalidad , Glotis/patología , Glotis/cirugía , Humanos , Inmunohistoquímica , Neoplasias Laríngeas/química , Neoplasias Laríngeas/mortalidad , Metástasis Linfática , Masculino , Persona de Mediana Edad , PronósticoRESUMEN
Endometrial carcinoma (EC) is traditionally characterized as endometrioid and nonendometrioid based on histopathologic phenotypes. Molecular-based classifications have been proposed, but are not widely implemented. Herein we examine molecular profiles between EC histologic subtypes. 3133 ECs were submitted between March 2011 and July 2014: 1634 Type I and 1226 Type II. In situ hybridization and immunohistochemistry were used to assess copy number and protein expression of selected genes. Sequenced variants in 47 genes were analyzed using the Illumina TruSeq Amplicon Cancer Panel. Type II EC included 628 cases of uterine serous cancer (USC), 136 cases of clear cell (CC), 361 cases of carcinosarcoma (CS), 38 cases of mucinous, and 36 cases of squamous cell. PI3K/Akt/mTOR pathway was most frequently dysregulated within Type I and mucinous histologies, least altered in CS and squamous. PD-L1 expression was highest in mucinous, absent in squamous. ER/PR expression was common in Type II, most frequent in USC, mucinous, and squamous. Receptor tyrosine kinase was frequently dysregulated in Type II disease: HER2 amplification highest in USC and CC, EGFR mutations exclusively seen in mucinous EC, KRAS mutations common in mucinous, squamous, and Type I, and c-MET overexpression high in CC and mucinous. BRCA1 and BRCA2 were most frequently mutated in CS. Grade 3 EC shares features of G1 tumor and Type II disease, most notably resembling CS. Endometrial carcinomas are a molecularly heterogeneous group of tumors. A histology-based molecular map can identify rational targets to optimize treatment and guide future clinical trials.
Asunto(s)
Carcinoma Endometrioide/patología , Neoplasias Endometriales/patología , Proteínas de Neoplasias/análisis , Transcriptoma , Adenocarcinoma de Células Claras/química , Adenocarcinoma de Células Claras/patología , Adenocarcinoma de Células Claras/secundario , Adenocarcinoma Mucinoso/química , Adenocarcinoma Mucinoso/patología , Adenocarcinoma Mucinoso/secundario , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma Endometrioide/química , Carcinoma Endometrioide/genética , Carcinoma Endometrioide/secundario , Carcinoma de Células Escamosas/química , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/secundario , Carcinosarcoma/química , Carcinosarcoma/patología , Carcinosarcoma/secundario , Reparación del ADN/genética , ADN de Neoplasias/genética , Neoplasias Endometriales/química , Neoplasias Endometriales/genética , Neoplasias Endometriales/secundario , Femenino , Dosificación de Gen , Humanos , Masculino , Persona de Mediana Edad , Proteínas de Neoplasias/genética , Transducción de Señal/efectos de los fármacos , Adulto JovenRESUMEN
Spindle cell and pleomorphic carcinomas are currently grouped among sarcomatoid carcinomas of the lung. Because of their unusual occurrence, these tumors have not been properly assessed by immunohistochemistry. We performed a comprehensive immunohistochemical analysis of 86 of these tumors. Seventy-four pleomorphic carcinomas (57 with differentiated elements) and 12 spindle cell carcinomas were subjected to immunohistochemistry with CAM5.2, cytokeratin (CK) 7, thyroid transcription factor 1, napsin A, CK5/6, p40, desmocollin 3, Sox2, calretinin, and D2-40. The percentage of positive tumor cells as well as the staining intensity were evaluated and scored. The spindle/giant elements were positive for CAM5.2 (93%), CK7 (79%), thyroid transcription factor 1 (41%), napsin A (20%), calretinin (20%), Sox2 (13%), CK5/6 (9%), p40 (8%), D2-40 (6%), and desmocollin 3 (3%). Of 29 cases in which immunohistochemistry was performed on spindle/giant cell and corresponding differentiated elements, 21 (72%) showed a consistent staining pattern in both components, whereas in 8 cases (28%), the immunophenotype in the spindle/giant cells was less lineage-specific than in the differentiated component. Therefore, we consider that 42% of neoplasms otherwise classified as sarcomatoid carcinoma can be reclassified as adenocarcinoma and 14% as squamous cell carcinoma, while the remaining 44% failed to show a more specific immunophenotype. The use of a comprehensive immunohistochemical panel allows reclassification of the majority of sarcomatoid carcinomas as poorly differentiated variants of adenocarcinoma or squamous cell carcinoma. Such reclassification will facilitate clinical management and allow molecular testing and pursuit of targeted treatment strategies. Application of immunohistochemistry should become the standard in the workup of pulmonary sarcomatoid carcinomas.
Asunto(s)
Adenocarcinoma/química , Biomarcadores de Tumor/análisis , Carcinoma de Células Escamosas/química , Carcinosarcoma/química , Inmunohistoquímica , Neoplasias Pulmonares/química , Adenocarcinoma/clasificación , Adenocarcinoma/patología , Adenocarcinoma del Pulmón , Biopsia , Carcinoma de Células Escamosas/clasificación , Carcinoma de Células Escamosas/patología , Carcinosarcoma/clasificación , Carcinosarcoma/patología , Diferenciación Celular , Linaje de la Célula , Humanos , Neoplasias Pulmonares/clasificación , Neoplasias Pulmonares/patología , Fenotipo , Valor Predictivo de las Pruebas , Reproducibilidad de los ResultadosRESUMEN
BACKGROUND: The primary objectives were to determine the objective response rate (ORR) and safety profile of ixabepilone in women with recurrent or persistent uterine carcinosarcoma (UCS). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Exploratory translational objectives included characterization of class III beta tubulin expression and its association with response, PFS, and OS. METHODS: Patients had measurable disease; up to two prior chemotherapeutic regimens were allowed, but must have included a taxane. Women received ixabepilone 40mg/m2 as a 3hour IV infusion on day 1 of a 21daycycle. Treatment was continued until disease progression or unacceptable toxicity occurred. RESULTS: Forty-two women were enrolled, with 34 eligible and evaluable. Median age was 68years. ECOG performance status was 0 in 56% of women, 38% had received radiation, and 15% had received 2 lines of chemotherapy. Overall ORR was 11.8% (4/34, 90% CI 4.2-25.1%); all were partial responses. Stable disease for at least 8weeks was achieved in 8 patients (23.5%). Median PFS and OS were 1.7mo and 7.7mo, respectively, with a median follow-up of 37mo. Six month PFS was 20.6%. Major grade≥3 toxicities were neutropenia (47%), fatigue (15%), dehydration (15%), hypertension (15%), and hyponatremia (15%); grade 2 peripheral neuropathy was reported in 18%. In this small sample size, class III beta tubulin expression in the primary tumor was not associated with the response to ixabepilone, PFS, or OS. CONCLUSION: In this cohort of women, single agent ixabepilone showed modest but insufficient clinical activity.
Asunto(s)
Antineoplásicos/uso terapéutico , Carcinosarcoma/tratamiento farmacológico , Epotilonas/uso terapéutico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Neoplasias Uterinas/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Antineoplásicos/efectos adversos , Carcinosarcoma/química , Carcinosarcoma/radioterapia , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Epotilonas/efectos adversos , Femenino , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia/química , Criterios de Evaluación de Respuesta en Tumores Sólidos , Retratamiento , Tasa de Supervivencia , Tubulina (Proteína)/análisis , Moduladores de Tubulina/uso terapéutico , Neoplasias Uterinas/química , Neoplasias Uterinas/radioterapiaRESUMEN
Adrenocortical carcinomas (ACCs) with sarcomatous areas represent an extremely rare type of highly aggressive malignancy of unknown molecular pathogenesis. The current study was planned to gain insight into its molecular genetics using a targeted next-generation sequencing approach and to explore the status of epithelial-mesenchymal transition (EMT)-associated markers (E-/P-/N-cadherins, MMP-2/-9 and caveolin-1), downstream transcriptional regulators of EMT-related signaling pathways (ZEB-1/-2, Slug), stem cell factors (Oct3/4, LIN28, SOX2, SO17, NANOG, CD133, nestin), and markers of adrenocortical origin/tumorigenesis (SF-1, ß-catenin, p53) in phenotypically diverse tumor components of 6 cases. Thirteen pathogenic variants of ACC-associated TP53 and CTNNB1 genes were detected in epithelial and/or nonepithelial components in 4 out of 6 tumors. Three cases had identical mutations in distinct components, 1 of which contained TP53/CTNNB1 in 3 out of 5 components, whereas 1 harbored a single TP53 mutation only in the nonepithelial component. By immunohistochemistry, SF-1 and E-/P-/N-cadherins were found positive only in the epithelial component of all cases, whereas the nonepithelial components were mainly enriched for nestin, ZEB-1, and MMP-2/-9. ß-Catenin demonstrated an aberrant nuclear localization in the sarcomatoid component of 5 cases, whereas p53 was strongly positive in nonepithelial constituent in 4 of 6 cases. In summary, we have shown that Wnt/ß-catenin signaling pathway dysregulation and mutational inactivation of TP53 are common genetic events in sarcomatoid ACCs, a subset of which being monoclonal in origin. These tumors are enriched for EMT-related markers and stem cell factors, potentially conferring a poor prognosis, which might be exploited as novel therapeutic targets.
Asunto(s)
Neoplasias de la Corteza Suprarrenal/diagnóstico , Carcinoma Corticosuprarrenal/diagnóstico , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Carcinosarcoma/diagnóstico , Secuenciación de Nucleótidos de Alto Rendimiento , Inmunohistoquímica , Neoplasias de la Corteza Suprarrenal/química , Neoplasias de la Corteza Suprarrenal/genética , Neoplasias de la Corteza Suprarrenal/patología , Carcinoma Corticosuprarrenal/química , Carcinoma Corticosuprarrenal/genética , Carcinoma Corticosuprarrenal/patología , Adulto , Anciano , Biopsia , Carcinosarcoma/química , Carcinosarcoma/genética , Carcinosarcoma/patología , Análisis Mutacional de ADN , Células Epiteliales/química , Células Epiteliales/patología , Transición Epitelial-Mesenquimal , Europa (Continente) , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Mutación , Células Madre Neoplásicas/química , Células Madre Neoplásicas/patología , Factores de Transcripción/análisis , Factores de Transcripción/genética , Vía de Señalización Wnt , Adulto JovenRESUMEN
OBJECTIVE: Evidence of potential prognostic and predictive value for nestin was investigated in well-annotated uterine cancers (UCs). METHODS: Nestin expression and previously-published biomarkers were evaluated by immunohistochemistry (IHC) in UC tissue microarrays. Biomarkers were categorized as low vs. high, and nestin was cut at 10% positive staining. Relationship between nestin and clinicopathologic factors, biomarkers and outcome were evaluated using exact/log-rank testing or logistic/Cox modeling. RESULTS: There were 323 eligible cases, 34% had advanced stage disease, 37% had type II disease, and 5% were carcinosarcomas. High nestin, observed in 19% of cases, was more common in advanced vs. early stage disease, type II cancers or uterine carcinosarcoma vs. type I cancers, grade 3 disease, positive lymphovascular space invasion (LVSI) and tumors >6cm (p<0.05). Nestin was inversely correlated with ER, PR and TFF3, and correlated with p53 and IMP3. Women with high vs. low nestin had worse progression-free survival (PFS) and cancer-specific survival overall, and worse PFS in the subset who received no adjuvant therapy or radiation, or had early stage, type I disease or tumors with both low and high ER, PR, TFF3, PTEN, p53 or IMP3. The relationship between nestin and PFS was independent of stage, LVSI and risk categorization but not type of UC. CONCLUSIONS: High nestin was more common in UCs with aggressive features and poor outcome. Nestin may represent a predictive biomarker for treatment selection for patients previously considered to be lower risk and a candidate for no or radiation-based adjuvant therapy, and compliment ER/PR testing.
Asunto(s)
Adenocarcinoma/química , Biomarcadores de Tumor/análisis , Carcinosarcoma/química , Nestina/análisis , Neoplasias Uterinas/química , Neoplasias Uterinas/patología , Adenocarcinoma/patología , Adenocarcinoma/terapia , Anciano , Carcinosarcoma/patología , Carcinosarcoma/terapia , Supervivencia sin Enfermedad , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Clasificación del Tumor , Invasividad Neoplásica , Estadificación de Neoplasias , Nestina/genética , Fosfohidrolasa PTEN/análisis , Péptidos/análisis , Péptidos/genética , Valor Predictivo de las Pruebas , ARN Mensajero/análisis , Proteínas de Unión al ARN/genética , Receptores de Estrógenos/análisis , Receptores de Estrógenos/genética , Receptores de Progesterona/análisis , Receptores de Progesterona/genética , Medición de Riesgo , Tasa de Supervivencia , Análisis de Matrices Tisulares , Factor Trefoil-3 , Proteína p53 Supresora de Tumor/genética , Neoplasias Uterinas/terapiaRESUMEN
Previously, we generated a preclinical mouse prostate tumor model based on PSA-Cre driven inactivation of Pten. In this model homogeneous hyperplastic prostates (4-5m) developed at older age (>10m) into tumors. Here, we describe the molecular and histological characterization of the tumors in order to better understand the processes that are associated with prostate tumorigenesis in this targeted mouse Pten knockout model. The morphologies of the tumors that developed were very heterogeneous. Different histopathological growth patterns could be identified, including intraductal carcinoma (IDC), adenocarcinoma and undifferentiated carcinoma, all strongly positive for the epithelial cell marker Cytokeratin (CK), and carcinosarcomas, which were negative for CK. IDC pattern was already detected in prostates of 7-8 month old mice, indicating that it could be a precursor stage. At more than 10 months IDC and carcinosarcoma were most frequently observed. Gene expression profiling discriminated essentially two molecular subtypes, denoted tumor class 1 (TC1) and tumor class 2 (TC2). TC1 tumors were characterized by high expression of epithelial markers like Cytokeratin 8 and E-Cadherin whereas TC2 tumors showed high expression of mesenchyme/stroma markers such as Snail and Fibronectin. These molecular subtypes corresponded with histological growth patterns: where TC1 tumors mainly represented adenocarcinoma/intraductal carcinoma, in TC2 tumors carcinosarcoma was the dominant growth pattern. Further molecular characterization of the prostate tumors revealed an increased expression of genes associated with the inflammatory response. Moreover, functional markers for senescence, proliferation, angiogenesis and apoptosis were higher expressed in tumors compared to hyperplasia. The highest expression of proliferation and angiogenesis markers was detected in TC2 tumors. Our data clearly showed that in the genetically well-defined PSA-Cre;Pten-loxP/loxP prostate tumor model, histopathological, molecular and biological heterogeneity occurred during later stages of tumor development.
Asunto(s)
Carcinoma/genética , Fosfohidrolasa PTEN/deficiencia , Neoplasias de la Próstata/genética , Adenocarcinoma/química , Adenocarcinoma/genética , Adenocarcinoma/patología , Animales , Apoptosis/genética , Biomarcadores , Biomarcadores de Tumor , Cadherinas/análisis , Carcinoma/química , Carcinoma/patología , Carcinosarcoma/química , Carcinosarcoma/genética , Carcinosarcoma/patología , Senescencia Celular/genética , Progresión de la Enfermedad , Células Epiteliales/química , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Inflamación/genética , Queratinas/análisis , Masculino , Mesodermo/química , Ratones , Ratones Endogámicos , Ratones Noqueados , Proteínas de Neoplasias/análisis , Neovascularización Patológica/genética , Neovascularización Patológica/patología , Hiperplasia Prostática/genética , Hiperplasia Prostática/patología , Neoplasias de la Próstata/química , Neoplasias de la Próstata/clasificación , Neoplasias de la Próstata/patología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , ARN Neoplásico/biosíntesis , ARN Neoplásico/genética , Células del Estroma/químicaRESUMEN
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare malignancy. METHODS: A total of 69 patients with PSC treated at a single institution in southern China with long-term follow-up were evaluated in this study. We analyzed the clinical characteristics, immunohistochemical profiles, epidermal growth factor receptor mutation status, K-RAS mutation status, treatments, and prognosis. RESULTS: PSC mainly occurred in young male patients with a history of smoking. Most patients received multimodality treatments and the majority had early-stage disease. The median survival time was 19.1 months, and the 5-year survival rate was 17.4%. The patients without distant metastasis, with normal or higher body mass index (≥18.5), with normal hemoglobin, with smaller tumor size (≤4 cm), and those who received complete resection had significantly better overall survival (P<0.05). The patients with pleomorphic carcinoma had much worse prognosis. In a Cox regression model, M stage, pathology, and having received a complete resection were independent prognostic factors (P<0.05). CONCLUSIONS: PSC is a unique lung malignancy with poor prognosis. Patients receiving complete resection had better prognosis, likely a reflection of early-stage disease. Neither neoadjuvant nor adjuvant chemotherapy improved patient survival for those with early-stage disease. The retrospective design and small sample size limited the generalizability. Future multicenter collaborations may be necessary to determine the optimal treatment.
Asunto(s)
Carcinoma/patología , Carcinoma/terapia , Carcinosarcoma/terapia , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/terapia , Blastoma Pulmonar/terapia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/química , Carcinoma/secundario , Carcinoma de Células Gigantes/química , Carcinoma de Células Gigantes/secundario , Carcinoma de Células Gigantes/terapia , Carcinosarcoma/química , Carcinosarcoma/secundario , Terapia Combinada , Supervivencia sin Enfermedad , Receptores ErbB/genética , Femenino , Estudios de Seguimiento , Humanos , Queratinas/análisis , Neoplasias Pulmonares/química , Masculino , Persona de Mediana Edad , Mucina-1/análisis , Proteínas Nucleares/análisis , Pronóstico , Proteínas Proto-Oncogénicas p21(ras)/genética , Blastoma Pulmonar/química , Blastoma Pulmonar/secundario , Proteínas S100/análisis , Tasa de Supervivencia , Factor Nuclear Tiroideo 1 , Factores de Transcripción/análisis , Vimentina/análisis , Adulto JovenRESUMEN
Cutaneous metastasis of uterine cancer is rare and is often associated with late-stage disease. Most uterine malignancies are endometrial adenocarcinomas, but a small subset is uterine carcinosarcoma, also known as malignant mixed Mullerian tumors. Uterine carcinosarcomas are highly aggressive tumors with an average 5-year survival rate of 26%-34%. Metastases most commonly occur in the abdominal wall, lung, and bone. Cutaneous metastasis is exceedingly rare and may pose a diagnostic challenge. The authors report a 57-year-old woman with multiple subcutaneous nodules on the face and trunk. A biopsy revealed similar morphology and staining characteristics as the sarcomatous component of the primary uterine carcinosarcoma. Histopathological features and immunophenotypical characteristics of the metastatic tumor are detailed in comparison with the original tumor. A review of the literature is also provided.
Asunto(s)
Carcinosarcoma/secundario , Neoplasias Cutáneas/secundario , Neoplasias Uterinas/patología , Biomarcadores de Tumor/análisis , Biopsia , Carcinosarcoma/química , Progresión de la Enfermedad , Resultado Fatal , Femenino , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Neoplasias Cutáneas/química , Neoplasias Uterinas/químicaAsunto(s)
Carcinosarcoma/secundario , Neoplasias Pulmonares/patología , Suelo de la Boca/patología , Neoplasias de la Boca/secundario , Biomarcadores de Tumor/análisis , Biopsia , Carcinosarcoma/química , Carcinosarcoma/cirugía , Quimioradioterapia Adyuvante , Resultado Fatal , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/química , Neoplasias Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Suelo de la Boca/química , Suelo de la Boca/cirugía , Neoplasias de la Boca/química , Neoplasias de la Boca/cirugía , Neumonectomía , Factores de Tiempo , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
Primary liver carcinosarcoma is rare. Here we report an unusual case of liver carcinosarcoma containing combined hepatocellular cholangiocarcinoma. A mass in the right liver lobe of a 45-year-old man was accidentally discovered by ultrasonic inspection and computed tomography (CT) scan. Surgical resection was performed following a diagnosis of primary liver cancer. Micropathologically, both carcinomatous and sarcomatous elements were present, and diagnosis of liver carcinosarcoma was confirmed. The carcinomatous element consisted of hepatocellular carcinoma and foci of cholangiocellular carcinoma. The sarcomatous element was composed of spindle cells and bizarre cells, as well as foci of osteosarcoma and chondrosarcoma. Hepatocellular carcinoma cells diffusely expressed both hepatocyte specific markers cytokeratin (CK) 8/18 and cholangiocyte specific markers CK19, and sarcoma cells were positive for vimentin. Interestingly, both carcinomatous and sarcomatous cells expressed epithelial membrane antigen. CD117-positive ductular reactions and small undifferentiated cells were observed. A liver progenitor cell origin of the liver carcinosarcoma was proposed.
Asunto(s)
Neoplasias de los Conductos Biliares/patología , Carcinosarcoma/patología , Colangiocarcinoma/patología , Hallazgos Incidentales , Neoplasias Hepáticas/patología , Neoplasias de los Conductos Biliares/química , Neoplasias de los Conductos Biliares/cirugía , Biomarcadores de Tumor/análisis , Biopsia , Carcinosarcoma/química , Carcinosarcoma/cirugía , Colangiocarcinoma/química , Colangiocarcinoma/cirugía , Hepatectomía , Humanos , Inmunohistoquímica , Neoplasias Hepáticas/química , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
GATA binding protein 3 (GATA3) is a recently described immunohistochemical marker that has proven useful in the characterization of breast and urothelial carcinomas. However, the expression pattern of GATA3 in mesonephric proliferations is largely unknown. The aim of this study was to examine the immunohistochemical expression of GATA3 in cervicovaginal mesonephric lesions and compare it to its expression in endocervical and endometrial adenocarcinomas and cervicovaginal endometriosis. A cohort of 107 cases, including 33 cases of mesonephric lesions and 74 cases of nonmesonephric lesions, was selected for the study. Of 33 mesonephric lesions, 31 (94%) cases (16 remnants, 12 hyperplasias, and 3 adenocarcinomas) were strongly and diffusely positive in tumor cell nuclei for GATA3. The remaining 2 mesonephric carcinosarcomas showed focal nuclear staining and rare nuclear positivity, respectively. Of 36 endocervical adenocarcinomas, 33 (92%) were negative for GATA3 and the remaining revealed focal weak nuclear staining. Of 34 endometrial adenocarcinomas, 32 (94%) were negative, whereas 2 showed rare nuclear positivity. All 4 cases of endometriosis were negative. The benign endocervical epithelium and the benign endometrium in most cases lacked GATA3 expression, whereas the benign squamous epithelium in the majority exhibited nuclear basal and parabasal staining pattern. Our study demonstrates that GATA3 protein is expressed in most mesonephric lesions, regardless of them being benign or malignant. In contrast, GATA3 is absent in the majority of endometrial and endocervical adenocarcinomas. These results support that GATA3 immunostain can be a useful tool in differentiating mesonephric lesions from endocervical and endometrial adenocarcinomas.